

Recommendations from York and Scarborough Medicines Commissioning Committee August 2015

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Aflibercept intravitreal injection (Eylea®)	Diabetic macular oedema	Approved	Approved in line with NICE TA 346 .	An option as per NICE criteria.	Red	An additional option to ranibizumab. NICE costing here .
Secukinumab s/c injection (Cosentyx®)	Moderate to severe plaque psoriasis	Approved	Approved in line with NICE TA 350 .	An option as per NICE criteria.	Red	An additional option. Savings may be achieved where IV options might otherwise be used. NICE costing here .
Dexamethasone intravitreal implant (Ozurdex®)	Diabetic macular oedema	Approved	Approved in line with NICE TA 349	An option as per NICE criteria.	Red	1 case/100,000 population Cost of £7,845 per annum. NICE costing here .
Cangrelor (Kengrexal®)	Reduction of thrombotic	Not approved	NICE terminated appraisal due to lack of cost	Not recommended – a submission to MCC	Grey	Nil

	cardiovascular events in patients with CAD undergoing PCI (as license)		effectiveness information.	would be required to consider the treatment.		
Biquelle® XL (quetiapine fumarate)	Licensed indications	Approved	Branded generic offering better value to the NHS.	The CCG preferred choice where quetiapine XL (Seroquel XL) is indicated.	Amber as per formulary.	Projected £59K as product offering a 56% saving compared to Seroquel.
Eppinix® XL (ropinirole)	Parkinson's Disease	Approved	Branded generic offering better value to the NHS.	When indicated: 1 st choice -immediate release formulation. MR/XL formulation restricted to use when genuine compliance problems or in patients who are struggling with on/off symptoms.	Amber-specialist initiation.	Projected £85K as product offering 55% saving compared to Requip XL. ¹
Repinex® XL (ropinirole)	Parkinsons Disease	Approved	Branded generic offering better value to the NHS.	When indicated: 1st choice - immediate release formulation. MR/XL formulation restricted to use when genuine compliance problems or in patients who are struggling with on/off symptoms.	Amber – specialist initiation.	Projected £77K as product offering a 50% saving compared to Requip XL. ¹

Laxido® Paediatric sachets (macrogol 3350)	Chronic constipation/faecal impaction in children as per license	Approved	Branded generic offering better value to the NHS.	The CCG preferred choice when a macrogol is indicated.	Green	Projected £8K saving as product offering a 32% saving compared to Movicol paediatric.
Neditol® XL capsules (tolterodine)	Overactive bladder syndrome	Approved	Branded generic offering better value to the NHS.	The CCG preferred choice when tolterodine XL is indicated.	Green	Projected £72K saving as product offering a 50% saving compared to Detrusitol XL.
Sirdupla® 25 /125 and 25/250 microgram MDI (Salmeterol and fluticasone)	Asthma	Approved	Offers better value to the NHS compared to Seretide and Fostair.	Sirdupla is indicated where fluticasone/salmeterol is indicated as per NICE asthma guidance.	Green	Projected £500K* saving as product offering a 41% saving compared to Seretide® Evohaler
Fulvestrant 250 mg injection (Faslodex®)	Locally advanced or metastatic breast cancer	Not approved	Not supported on grounds of clinical and cost effectiveness on the proposed 4 th line use (after tamoxifen, anastrozole / letrozole and exemestane.)	Not recommended for use	Black	Nil
Tiopronin (unlicensed)	Cystinuria	Not approved	Proposed use to be re-reviewed by the committee upon receipt of revised	Not recommended for use	Black	Nil

			submission			
Jaydess® 13.5mg interuterine device (Levonorgestrel)	Long acting intrauterine contraception	Approved	Approved for use by GP practices commissioned to provide contraception services by North Yorkshire County Council	When this route chosen, for use up to 3 years Jaydess is 1 st line. For use up to 5 years, Mirena is 1 st line as per public health commissioning policy.	Green	Nil – costs reimbursed by local authority where use in line with specification.
GlucoRx® blood glucose monitoring device	Diabetes mellitus	Approved	The CCG blood glucose monitoring device of choice for type 2 diabetes.	Device of choice where blood glucose monitoring is indicated.	Green	Offers savings to the CCG.
Loperamide tablets or capsules	Diarrhoea	Approved	Due to price fluctuations, routinely the formulation with the lowest acquisition cost should be used.	Loperamide is antitomotility drug of choice. Patients with high stoma output – the tablet formulation are the recommended choice.	Green	Savings may be achieved by choosing lowest cost formulation.
Bramox® tablets (Midodrine)	Orthostatic hypotension	Approved	Formulary position unchanged – New licensed formulation available.	Formulary position – midodrine indicated for postural hypotension in patients who have failed fludrocortisone and standard non pharmacological measures.	Amber – specialist initiation.	Savings may be realised from use of a licensed product.

¹savings are an estimate if each individual ropinirole product was implemented alone on total spend. The savings projected where both drugs are implemented will not return the cumulative savings presented across both entries.

Other items to approve:

CCG Medal ranking and guidelines – adult oral nutritional products.



Item 8c Adult oral nutrition formulary for the appropriate u
Item 8c Guidelines

NHS England updated commissioning intentions – to note the update of specialist items. <http://www.england.nhs.uk/2015/07/02/annual-investment-decisions/>